Sponsors (2)
The bill leverages federal procurement to expand demand and transparency for U.S. biobased products and strengthen domestic biomanufacturing, but it risks higher government procurement costs, added agency administrative burden, and potential loopholes that could blunt benefits to domestic suppliers.
U.S. biobased manufacturers, biorefineries, and farmers will face increased federal demand and an explicit procurement preference, likely boosting domestic production and jobs in biomanufacturing and agricultural feedstocks.
Federal contracting officers and procurement systems will receive training and catalog updates within two years, making it easier for agencies to identify and buy eligible biobased products and smoothing implementation.
Policymakers, investors, and the public will gain better transparency and oversight because agencies must track/report economic value and geographic distribution of biomanufacturing facilities and GAO will review program implementation.
Taxpayers and some agencies may face higher procurement costs because price preferences for biobased items can raise purchase prices and displace lower-cost alternatives.
Domestic small biobased manufacturers and farmers may receive less support than intended if Buy American exceptions permit purchase of non-U.S. biobased products.
Federal contracting staff and agencies will face added administrative burden from new reporting, verification, and training requirements, consuming time and resources to comply.
Based on analysis of 2 sections of legislative text.
Introduced September 3, 2025 by Todd Young · Last progress September 3, 2025
Directs federal agencies to strengthen and expand the Federal Biobased Markets Program by tightening procurement targets, promoting U.S.-made biobased products, and improving reporting and verification. It requires annual updates to procurement goals, adds a preference for biobased products produced wholly or partly in the United States, expands agency training and catalog updates, and directs a Comptroller General review within two years.